10x Genomics Q2 EPS $(0.53) Misses $(0.39) Estimate, Sales $146.82M Beat $138.97M Estimate
Portfolio Pulse from saritha@benzinga.com
10x Genomics reported Q2 losses of $(0.53) per share, missing the analyst consensus estimate of $(0.39) by 35.9%. However, the company's quarterly sales of $146.82 million beat the estimate of $138.97 million by 5.65%. This represents a 28.10% increase over sales from the same period last year.
August 04, 2023 | 2:26 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
10x Genomics' Q2 earnings per share missed estimates, but sales exceeded expectations. This mixed result could lead to uncertain market reactions.
10x Genomics reported a larger than expected loss per share, which is typically negative for the stock price. However, the company also reported higher than expected sales, which is generally positive. The mixed results make the short-term impact on the stock price uncertain.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100